Compounds > cyproterone acetate
Page last updated: 2024-08-21

cyproterone acetate and fibrinogen

cyproterone acetate has been researched along with fibrinogen in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (40.00)18.2507
2000's2 (40.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abramovici, Y; Boudou, P; Cathelineau, G; Conard, J; Consoli, S; Fiet, J; Hardy, N; Vexiau, P1
Andersen, LF; Gram, J; Jespersen, J; Skouby, SO1
Geleijnse, JM; Giltay, EJ; Gooren, LJ; Schouten, EG; Stehouwer, CD; Verhoef, P1
del Rey Sánchez, JM; Escobar-Morreale, HF; Luque-Ramírez, M; Matíes, M; Mendieta-Azcona, C1
Adonakis, G; Armeni, AK; Decavalas, G; Georgopoulos, NA; Karela, A; Markantes, G; Saltamavros, AD; Vervita, V1

Trials

5 trial(s) available for cyproterone acetate and fibrinogen

ArticleYear
17 beta-Estradiol: oral or parenteral administration in hyperandrogenic women? Metabolic tolerance in association with cyproterone acetate.
    Fertility and sterility, 1995, Volume: 63, Issue:3

    Topics: Administration, Cutaneous; Administration, Oral; Angiotensinogen; Antithrombin III; Apolipoproteins; Blood Coagulation; Blood Glucose; Blood Pressure; Cholesterol; Cholesterol, HDL; Cyproterone Acetate; Drug Therapy, Combination; Estradiol; Estrone; Female; Fibrinogen; Fibrinolysis; Glucose Tolerance Test; Humans; Hyperandrogenism; Insulin; Plasminogen; Premenopause; Prospective Studies; Sex Hormone-Binding Globulin

1995
Effects of hormone replacement therapy on hemostatic cardiovascular risk factors.
    American journal of obstetrics and gynecology, 1999, Volume: 180, Issue:2 Pt 1

    Topics: Cardiovascular Diseases; Cyproterone Acetate; Estradiol; Estrogen Replacement Therapy; Factor VII; Female; Fibrinogen; Hemostasis; Humans; Lipoprotein(a); Middle Aged; Placebos; Plasminogen Activator Inhibitor 1; Postmenopause; Risk Factors; Tissue Plasminogen Activator

1999
Oral and transdermal estrogens both lower plasma total homocysteine in male-to-female transsexuals.
    Atherosclerosis, 2003, Volume: 168, Issue:1

    Topics: Administration, Cutaneous; Administration, Oral; Adult; Androstane-3,17-diol; Biomarkers; C-Reactive Protein; Creatinine; Cyproterone Acetate; Cysteine; Estradiol; Estrogens; Female; Fibrinogen; Folic Acid; Follicle Stimulating Hormone; Homocysteine; Humans; Luteinizing Hormone; Male; Middle Aged; Randomized Controlled Trials as Topic; Serum Albumin; Statistics as Topic; Testosterone; Time Factors; Transsexualism

2003
Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking.
    European journal of endocrinology, 2009, Volume: 160, Issue:3

    Topics: Adult; Androgen Antagonists; Blood Coagulation; Blood Platelets; Case-Control Studies; Contraceptives, Oral, Hormonal; Cyproterone Acetate; Drug Combinations; Endothelium, Vascular; Ethinyl Estradiol; Female; Fibrinogen; Homocysteine; Humans; Hypoglycemic Agents; Metformin; Obesity; Partial Thromboplastin Time; Polycystic Ovary Syndrome; Prothrombin; Smoking; Young Adult

2009
Increased plasma viscosity in young women with polycystic ovary syndrome using an oral contraceptive containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2011, Volume: 27, Issue:12

    Topics: Adolescent; Adult; Blood Viscosity; Body Mass Index; Chemistry, Pharmaceutical; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Cyproterone Acetate; Dose-Response Relationship, Drug; Ethinyl Estradiol; Female; Fibrinogen; Humans; Polycystic Ovary Syndrome; Triglycerides; Young Adult

2011